UBS Downgrades Zymogenetics (ZGEN) to Neutral; Acquired By Bristol-Myers (BMY)
Tweet Send to a Friend
UBS downgrades Zymogenetics (Nasdaq: ZGEN) from Buy to Neutral.
UBS analyst says ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
UBS analyst says ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
